Sorrento Therapeutics, Inc.
Cell penetrating peptide inhibitors of p53-MDM2 interaction
Last updated:
Abstract:
Provided are compounds having the Formula I or II: ##STR00001## and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancers.
Status:
Grant
Type:
Utility
Filling date:
25 Jan 2018
Issue date:
10 Mar 2020